This post-AAD interview with Chovatiya covered takeaways regarding recent data on upadacitinib for vitiligo, tapinarof for eczema, and lutikizumab for hidradenitis suppurativa.
These new, positive data from the ADORING Phase 3 development program showed no new safety signals with long-term use as well as a significant reduction in disease burden.
This research provides an early analysis of plaque psoriasis patients within routine clinical practice settings and outside of a clinical trial setting.
In this discussion, Dr. Jeff Yu explores the topic of atopic dermatitis treatment news and the upcoming decision by the FDA on tapinarof for this skin disease.